Esperanza Welsh

1.6k total citations
22 papers, 1.1k citations indexed

About

Esperanza Welsh is a scholar working on Dermatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Esperanza Welsh has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Dermatology, 6 papers in Epidemiology and 4 papers in Infectious Diseases. Recurrent topics in Esperanza Welsh's work include Psoriasis: Treatment and Pathogenesis (3 papers), Nail Diseases and Treatments (2 papers) and Drug-Induced Adverse Reactions (2 papers). Esperanza Welsh is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (3 papers), Nail Diseases and Treatments (2 papers) and Drug-Induced Adverse Reactions (2 papers). Esperanza Welsh collaborates with scholars based in Mexico, United States and Brazil. Esperanza Welsh's co-authors include Oliverio Welsh, Lucio Vera‐Cabrera, William H. Eaglstein, Stephen C. Davis, Alex Cazzaniga, Carlos Ricotti, Patricia M. Mertz, Robert S. Kirsner, Francisco A. Kerdel and Jorge Ocampo‐Candiani and has published in prestigious journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology and Postgraduate Medical Journal.

In The Last Decade

Esperanza Welsh

19 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Esperanza Welsh Mexico 12 417 272 204 202 189 22 1.1k
Maria Letícia Cintra Brazil 17 197 0.5× 259 1.0× 125 0.6× 102 0.5× 63 0.3× 97 932
Ali Asilian Iran 22 300 0.7× 701 2.6× 63 0.3× 35 0.2× 118 0.6× 71 1.4k
Aayushi Uberoi United States 14 338 0.8× 234 0.9× 45 0.2× 241 1.2× 209 1.1× 22 936
Ahmad Nofal Egypt 19 618 1.5× 513 1.9× 76 0.4× 135 0.7× 23 0.1× 79 1.3k
Carlos Ricotti United States 12 175 0.4× 235 0.9× 35 0.2× 245 1.2× 248 1.3× 35 774
RameshM Bhat India 21 624 1.5× 560 2.1× 264 1.3× 69 0.3× 17 0.1× 98 1.3k
Theodore Rosen United States 19 697 1.7× 565 2.1× 133 0.7× 128 0.6× 12 0.1× 74 1.3k
G. E. Piérard Belgium 17 341 0.8× 461 1.7× 78 0.4× 93 0.5× 20 0.1× 77 963
Jianjun Qiao China 19 326 0.8× 245 0.9× 283 1.4× 255 1.3× 9 0.0× 90 1.2k
Gita Faghihi Iran 20 190 0.5× 722 2.7× 44 0.2× 42 0.2× 52 0.3× 85 1.2k

Countries citing papers authored by Esperanza Welsh

Since Specialization
Citations

This map shows the geographic impact of Esperanza Welsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esperanza Welsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esperanza Welsh more than expected).

Fields of papers citing papers by Esperanza Welsh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esperanza Welsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esperanza Welsh. The network helps show where Esperanza Welsh may publish in the future.

Co-authorship network of co-authors of Esperanza Welsh

This figure shows the co-authorship network connecting the top 25 collaborators of Esperanza Welsh. A scholar is included among the top collaborators of Esperanza Welsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esperanza Welsh. Esperanza Welsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garza, Jesús Alberto Cárdenas‐de la, et al.. (2025). Treatment with spesolimab in patients with generalized pustular psoriasis: a review of real-world experience. Clinical and Experimental Dermatology. 50(9). 1733–1740.
2.
Cortés, Cristina, et al.. (2024). IncobotulinumtoxinA for Aesthetic Treatments: Review and Recommendations From Latin America. Dermatologic Surgery. 50(9S). S24–S34. 1 indexed citations
3.
Welsh, Esperanza, et al.. (2023). Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review. Anais Brasileiros de Dermatologia. 99(2). 319–320. 4 indexed citations
4.
Garza, Jesús Alberto Cárdenas‐de la, et al.. (2023). Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review. Clinical and Experimental Dermatology. 49(3). 286–288. 5 indexed citations
5.
Welsh, Esperanza, et al.. (2021). COVID‐19 dermatological manifestations: results from the Mexican Academy of Dermatology COVID‐19 registry. International Journal of Dermatology. 60(7). 879–881. 2 indexed citations
6.
Welsh, Esperanza, et al.. (2017). Cutaneous mucormycosis. Anais Brasileiros de Dermatologia. 92(3). 304–311. 100 indexed citations
7.
Martínez‐Cabriales, Sylvia Aidé, et al.. (2017). Actinomycetoma: a therapeutic challenge. Postgraduate Medical Journal. 94(1108). 126–126.
8.
Welsh, Esperanza. (2014). Contact Dermatitis: Therapeutics When Avoidance Fails. Journal of Allergy & Therapy. 5(4). 4 indexed citations
9.
Simko, Stephen J., Jeremy Jones, Mrinalini Bilgi, et al.. (2013). Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatric Blood & Cancer. 61(3). 479–487. 86 indexed citations
10.
Welsh, Oliverio, et al.. (2012). Actinomycetoma and advances in its treatment. Clinics in Dermatology. 30(4). 372–381. 61 indexed citations
11.
Welsh, Oliverio, Lucio Vera‐Cabrera, & Esperanza Welsh. (2010). Onychomycosis. Clinics in Dermatology. 28(2). 151–159. 140 indexed citations
12.
Davis, Stephen C., Carlos Ricotti, Alex Cazzaniga, et al.. (2007). Microscopic and physiologic evidence for biofilm‐associated wound colonization in vivo. Wound Repair and Regeneration. 16(1). 23–29. 310 indexed citations
13.
Welsh, Oliverio, Esperanza Welsh, Jorge Ocampo‐Candiani, Minerva Gómez, & Lucio Vera‐Cabrera. (2006). Dermatophytoses in Monterrey, México. Mycoses. 49(2). 119–123. 44 indexed citations
14.
Baumann, Leslie, et al.. (2006). Cosmetic dermatology: Beyond the beauty. 19(4). 287–289.
15.
Alster, Tina S., Elizabeth L. Tanzi, & Esperanza Welsh. (2005). Photorejuvenation of facial skin with topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a split-face comparison study.. PubMed. 4(1). 35–8. 57 indexed citations
16.
Baumann, Leslie, et al.. (2003). Cryoanalgesia With Dichlorotetrafluoroethane Lessens the Pain of Botulinum Toxin Injections for the Treatment of Palmar Hyperhidrosis. Dermatologic Surgery. 29(10). 1057–1060. 24 indexed citations
17.
Drosou, Anna, Robert S. Kirsner, Esperanza Welsh, Tory P. Sullivan, & Francisco A. Kerdel. (2003). Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses. Journal of Cutaneous Medicine and Surgery. 7(5). 382–386. 70 indexed citations
18.
Sullivan, Thomas P., Esperanza Welsh, Francisco A. Kerdel, Anne E. Burdick, & Robert S. Kirsner. (2003). Infliximab for hidradenitis suppurativa. British Journal of Dermatology. 149(5). 1046–1049. 113 indexed citations
19.
Burdick, Anne E., et al.. (2003). Axillary polymastia. Journal of the American Academy of Dermatology. 49(6). 1154–1156. 29 indexed citations
20.
Drosou, Anna, Robert S. Kirsner, Esperanza Welsh, Tory P. Sullivan, & Francisco A. Kerdel. (2003). Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses. Journal of Cutaneous Medicine and Surgery. 7(5). 382–386. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Letícia Cintra Breakdown of academic impact, for papers by Ali Asilian Breakdown of academic impact, for papers by Aayushi Uberoi Breakdown of academic impact, for papers by Ahmad Nofal Breakdown of academic impact, for papers by Carlos Ricotti Breakdown of academic impact, for papers by RameshM Bhat Breakdown of academic impact, for papers by Theodore Rosen Breakdown of academic impact, for papers by G. E. Piérard Breakdown of academic impact, for papers by Jianjun Qiao Breakdown of academic impact, for papers by Gita Faghihi
Rankless by CCL
2026